JP5992831B2 - 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 - Google Patents

非機能性オリゴマーｐ２ｘ７受容体に対する抗体 Download PDF

Info

Publication number
JP5992831B2
JP5992831B2 JP2012545019A JP2012545019A JP5992831B2 JP 5992831 B2 JP5992831 B2 JP 5992831B2 JP 2012545019 A JP2012545019 A JP 2012545019A JP 2012545019 A JP2012545019 A JP 2012545019A JP 5992831 B2 JP5992831 B2 JP 5992831B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
antibody
cell
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012545019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515013A (ja
JP2013515013A5 (https=
Inventor
ジュリアン・アレクサンダー・バーデン
アンガス・ギドリー−ベアード
グレン・ローランド・ピルキントン
Original Assignee
バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009906286A external-priority patent/AU2009906286A0/en
Application filed by バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド filed Critical バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド
Publication of JP2013515013A publication Critical patent/JP2013515013A/ja
Publication of JP2013515013A5 publication Critical patent/JP2013515013A5/ja
Application granted granted Critical
Publication of JP5992831B2 publication Critical patent/JP5992831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012545019A 2009-12-24 2010-12-23 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 Active JP5992831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009906286 2009-12-24
AU2009906286A AU2009906286A0 (en) 2009-12-24 Anti P2X7 receptor antibodies and fragments thereof
PCT/AU2010/001741 WO2011075789A1 (en) 2009-12-24 2010-12-23 Antibodies to non-functional oligomeric p2x7 receptors

Publications (3)

Publication Number Publication Date
JP2013515013A JP2013515013A (ja) 2013-05-02
JP2013515013A5 JP2013515013A5 (https=) 2014-02-13
JP5992831B2 true JP5992831B2 (ja) 2016-09-14

Family

ID=44194835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545019A Active JP5992831B2 (ja) 2009-12-24 2010-12-23 非機能性オリゴマーｐ２ｘ７受容体に対する抗体

Country Status (9)

Country Link
US (2) US8835609B2 (https=)
EP (2) EP3321285B1 (https=)
JP (1) JP5992831B2 (https=)
CN (1) CN102762595B (https=)
AU (1) AU2010336032C1 (https=)
BR (1) BR112012015561B1 (https=)
CA (1) CA2784345C (https=)
ES (2) ES2667003T3 (https=)
WO (1) WO2011075789A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360203B1 (en) 2001-01-17 2008-12-24 Intreat Pty Limited Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) * 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
EP3347474B1 (en) 2015-09-11 2020-11-04 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
CN109862883A (zh) 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
US11629184B2 (en) 2018-02-23 2023-04-18 Remd Biotherapeutics, Inc. Calcitonin gene-related peptide (CGRP) antagonist antibodies
EP3797164A4 (en) 2018-05-21 2022-03-02 Biosceptre (Aust) Pty Ltd CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES
WO2019229296A1 (en) 2018-05-29 2019-12-05 Teknologian Tutkimuskeskus Vtt Oy Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
WO2021019222A1 (en) * 2019-07-26 2021-02-04 Biosceptre (Uk) Limited P2x7 receptor targeted therapy
JP2024510739A (ja) * 2021-03-11 2024-03-11 バイオセプター （オースト） プロプライエタリー・リミテッド 新規な細胞治療システム
MX2023015028A (es) * 2021-09-01 2024-02-16 Biosceptre Aust Pty Ltd Nuevos aglutinantes del p2x7 disfuncional.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
WO1995033048A2 (en) 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
US5981218A (en) 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトＰ２ｘ４レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
EP1360203B1 (en) 2001-01-17 2008-12-24 Intreat Pty Limited Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
NZ565994A (en) * 2001-09-03 2010-02-26 Intreat Pty Ltd Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
JP2013515013A (ja) 2013-05-02
AU2010336032A1 (en) 2012-07-12
EP3321285A1 (en) 2018-05-16
EP2516470B1 (en) 2018-02-07
AU2010336032B2 (en) 2016-01-28
CN102762595B (zh) 2016-03-02
ES2667003T3 (es) 2018-05-09
US20120329076A1 (en) 2012-12-27
BR112012015561B1 (pt) 2019-11-12
CA2784345C (en) 2018-11-13
US9428587B2 (en) 2016-08-30
CN102762595A (zh) 2012-10-31
US8835609B2 (en) 2014-09-16
WO2011075789A1 (en) 2011-06-30
AU2010336032C1 (en) 2016-04-21
EP2516470A1 (en) 2012-10-31
US20150218283A1 (en) 2015-08-06
CA2784345A1 (en) 2011-06-30
BR112012015561A8 (pt) 2019-10-01
EP3321285B1 (en) 2019-04-24
ES2732021T3 (es) 2019-11-20
BR112012015561A2 (pt) 2017-01-31
EP2516470A4 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
JP5992831B2 (ja) 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US12129295B2 (en) Anti P2X7 receptor antibodies and fragments thereof
CN102143978A (zh) 抗p2x7肽和表位
HK1168365B (en) Anti p2x7 receptor antibodies and fragments thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160818

R150 Certificate of patent or registration of utility model

Ref document number: 5992831

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250